regul
upstream
cytokin
product
could
promis
strategi
treatment
suggest
pay
attent
dysregul
ifni
product
consider
cga
alk
sting
potenti
therapeut
target
prevent
cytokin
storm
approv
drug
like
suramin
alk
inhibitor
worthi
clinic
trial
novel
coronaviru
singl
strand
rna
viru
respons
ongo
sever
respiratori
ill
pneumonialik
infect
human
worldwid
regard
global
health
emerg
belong
cluster
sarscov
merscov
typei
interferon
ifni
activ
intracellular
pathogen
defens
influenc
develop
innat
immun
adapt
immun
dna
sensor
cyclic
gmpamp
synthas
cga
downstream
effector
sting
stimul
interferon
gene
also
known
eri
mita
control
transcript
mani
inflammatori
mediat
includ
type
type
iii
interferon
howev
abnorm
recognit
interpret
dangersuramin
interact
posit
charg
region
surround
axi
capsid
inhibit
multipl
enteroviru
associ
molecular
pattern
damp
cga
like
selfdna
releas
apoptot
cell
also
aris
human
inflammatori
diseas
sting
gainoffunct
mutant
respons
variou
devast
autoimmun
diseas
known
stingassoci
vasculopathi
onset
infanc
savi
excess
inflamm
induc
sting
disord
damag
bodi
cell
tissu
caus
savi
phenotyp
includ
system
inflamm
destruct
skin
lesion
interstiti
lung
diseas
sar
infect
mice
model
rapid
spread
viru
ultim
induc
delay
ifni
product
promot
sever
diseas
late
state
boost
accumul
pathogen
monocytemacrophag
result
lung
immunopatholog
vascular
leakag
suboptim
cell
respons
sar
patient
high
ifn
ifnstimul
chemokin
level
plu
robust
antivir
ifnstimul
gene
express
accompani
earli
sar
sequela
poor
clinic
cours
sepsi
lifethreaten
organ
dysfunct
caus
infect
silicainduc
lung
inflamm
sting
depend
disord
ifni
respons
also
report
lung
damag
level
level
cytokin
icu
patient
nonicu
patient
higher
healthi
adult
similar
phenomena
also
found
sar
patient
silicainduc
lung
inflamm
patient
given
prevent
cgasst
pathway
aberr
activ
may
suitabl
strategi
treatment
sever
lung
diseas
induc
sarscov
pathogen
suppos
sever
protein
pathway
potenti
target
figur
sting
popular
drug
target
immunosuppress
recent
year
sever
sting
regulatori
molecul
develop
academi
industri
unfortun
none
sting
directlytarget
molecul
market
yet
obtain
potenti
sting
safeti
inhibitor
screen
fdaapprov
drug
librari
use
virtual
screen
select
compound
screen
molecular
structur
compound
shown
figur
select
compound
evalu
two
cellbas
assay
sorafenib
potent
inhibit
vaccinia
viru
induc
product
cell
fig
hela
cell
sorafenib
inhibit
dsdna
induc
phosphoryl
dose
depend
incub
hour
hour
fig
data
indic
sorafenib
potent
inhibitor
sting
pathway
direct
stingsorafenib
bind
assay
might
give
evid
figur
sorafenib
shown
potent
sting
inhibitor
use
drug
target
sting
regulatori
protein
regul
ifni
product
also
potenti
strategi
meet
urgent
need
market
drug
recent
anaplast
lymphoma
kinas
alk
inhibitor
report
specif
effect
sting
antagonist
vitro
vivo
alk
directli
interact
epiderm
growth
factor
receptor
egfr
trigger
serinethreonin
protein
kinas
akt
phosphoryl
activ
interferon
regulatori
factor
nuclear
factor
signal
pathway
enabl
stingdepend
rigor
inflammatori
respons
thu
alktarget
drug
great
potenti
treat
moder
sever
lung
inflamm
covid
cga
cytosol
dna
sensor
upstream
sting
also
potenti
therapeut
target
ifni
regul
suramin
approv
antiparasit
drug
report
effect
cga
antagonist
displac
bound
dna
cga
suramin
report
entri
inhibitor
variou
virus
includ
dna
viru
rna
viru
clinic
trial
applic
suramin
submit
china
feb
cytokin
direct
antagonist
adalimumab
appli
clinic
trial
divers
cytokin
involv
patholog
thu
regul
upstream
cytokin
product
could
promis
strategi
collect
suggest
pay
attent
dysregul
ifni
product
consider
cga
alk
sting
potenti
therapeut
target
prevent
cytokin
storm
approv
drug
like
suramin
alk
inhibitor
worthi
clinic
trial
virtual
screen
cdigmp
bond
sting
crystal
complex
use
receptor
pdb
commerci
fdaapprov
drug
data
contain
compound
download
selleck
websit
twostep
molecular
dock
scheme
perform
success
use
discov
activ
molecul
system
virtual
screen
use
fdaapprov
drug
cga
alk
also
perform
potenti
compound
known
inhibitor
found
gener
procedur
follow
compound
dock
ligand
bind
pocket
rigidbodi
dock
approach
dock
program
use
default
paramet
two
hundr
compound
lowest
compound
form
least
two
hydrogen
bond
compound
polypeptid
type
iifn
bioassay
type
iifn
concentr
measur
previous
describ
cell
starv
fb
contain
dmem
h
infect
vaccinia
viru
report
cell
plant
plate
incub
human
cell
cultur
supernat
recombin
human
r
system
use
standard
h
later
cell
lyse
measur
luciferas
report
assay
system
promega
western
blot
hela
cell
plant
dish
cellsdish
transfect
indic
express
plasmid
h
hela
cell
treat
dsdna
sorafenib
indic
time
cell
lyse
lysi
buffer
triton
mm
nacl
mm
mm
mm
egta
mm
naf
mm
mm
dtt
contain
proteas
inhibitor
lysat
centrifug
supernat
incub
antiflag
bead
protein
ag
sepharos
amersham
plu
antiviperin
antigfp
antibodi
least
h
bead
wash
cold
pb
three
time
elut
dttcontain
sd
sampl
buffer
boil
min
western
blot
analysi
literatur
infer
work
support
ai
platform
name
drug
discoveri
brain
infin
intellig
pharma
co
ltd
thank
dr
youjun
xu
dr
weilin
zhang
help
comput
program
data
process
